智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属浙江信谊瑞爵制药有限公司(以下简称“信谊瑞爵”)收到美国食品药品监督管理局(以下简称“美国FDA”)的通知，其关于糠酸莫米松鼻喷雾剂(基本情况详阅正文，以下简称“该药品”)的简略新药申请(“ANDA”，即美国仿制药申请)已获得批准(“Approval”)。
糠酸莫米松鼻喷雾剂主要用于预防/治疗青少年和成人的季节性鼻炎，以及治疗成人伴有鼻息肉的慢性鼻窦炎。糠酸莫米松鼻喷雾剂最早由默克集团的先灵葆雅公司研发并于1997年在美国上市。2018年3月，信谊瑞爵就该药品向美国FDA提出ANDA申请，并于近日获得批准文号。自上海医药立项时起至本公告日，信谊瑞爵针对该药品已投入研发费用约人民币4,944.89万元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.